Single-Center Validation of the Second Revised International Staging System (R2-Iss) in a Population of Transplant-Eligible (Te) Newly-Diagnosed Multiple Myeloma (Ndmm) Treated with Bortezomib-Based Regimens
AuthID
P-018-3VV
P-018-3VV